Growth Metrics

Recursion Pharmaceuticals (RXRX) Leases (2022 - 2025)

Historic Leases for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Q3 2025 value amounting to $47.8 million.

  • Recursion Pharmaceuticals' Leases fell 14.62% to $47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.8 million, marking a year-over-year decrease of 14.62%. This contributed to the annual value of $65.9 million for FY2024, which is 9569.56% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Leases is $47.8 million, which was down 14.62% from $50.3 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Leases peaked at $65.9 million during Q4 2024, and registered a low of $33.3 million during Q4 2022.
  • Over the past 4 years, Recursion Pharmaceuticals' median Leases value was $35.1 million (recorded in 2023), while the average stood at $41.2 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Leases soared by 9569.56% in 2024 and then fell by 14.62% in 2025.
  • Quarter analysis of 4 years shows Recursion Pharmaceuticals' Leases stood at $33.3 million in 2022, then increased by 1.23% to $33.7 million in 2023, then soared by 95.7% to $65.9 million in 2024, then dropped by 27.42% to $47.8 million in 2025.
  • Its Leases was $47.8 million in Q3 2025, compared to $50.3 million in Q2 2025 and $53.2 million in Q1 2025.